Skip to content

C.D. PHARMA

Active
Private limited company (pre-2019)founded 199729 yrs activeAllée de la Tour-Renard 15, 1400 Nivelles, BelgiumKBO/BCE: BE 0461.479.280
Summary

C.D. PHARMA has been active since 1997 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €25,306 and a net result of -€10,408. Equity is shrinking by ~15% per year and would, assuming unchanged policy, indicatively turn negative around fiscal year 2028. The computed 12-month bankruptcy probability is 1.0% (low).

Checked score

Score 2025
Axes · tick = 2024
Profitability14=
Solvency34▼-4
Growth32=
Track record100
Bankruptcy probability, 12 months
1.0% Low
0%0.5%1.5%4%10%≥ 25%
Credit up to €500 at 30 days only on tighter terms
Liquidity short (current ratio 0.0 against 0.0 in 2024; short-term debt: 90.6% of total assets), and 90.6% of the assets are financed with debt.
Credit check for your own amount and term

Show the recommended maximum : and see how the verdict changes with amount, term and advance.

Signals

Six signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · No NACE activity registered
No NACE activity is registered in the KBO, which is more common among companies that later fail.
KBO · activities
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation date
Age against the risk zone
highest failure risk from 2 to 8 years 29 years 0 30 y
raises risk · Annual accounts: weaker financial profile
The latest annual accounts show a weaker profile in solvency, result or liquidity than companies that stay afloat.
NBB · annual accounts 2025
Solvency, return and age of the figures
Solvency
9.4%
Return on assets
-3.8%
Age of the figures
10 mo
raises risk · Higher-failure-rate region
In this region companies fail more often than in the rest of the country.
KBO · registered office
raises risk · Persistent losses
Two consecutive loss-making years (2024 and 2025); equity is also lower. May indicate structural pressure on profitability.
NBB · annual accounts 2025
Net result per financial year
1819202122232425
2018 to 2025 · latest year -€10,408
neutral · Latest accounts filed on time
The financial year that closed on 30-11-2025 was due by 30-06-2026 and was filed on 12-05-2026, 49 days ahead of the deadline.
NBB · 10 filings
Deviation from the deadline
2025
49 d early
2024
25 d early
2023
47 d early
2022
38 d early
2021
28 d early
2020
54 d early
2019
39 d early
← before the deadline after the deadline →
tick = median of all Belgian filings

This company filed its last 7 accounts on average 40 days before the deadline; the Belgian median for financial year 2024 is 4 days before the deadline, and 38% of all filings were late.

Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 30-11-2026 and is due by 30-06-2027. Nothing is late today.
Companies Code · seven months
Position in the running window
28-09-2026 today30-11-2026 close30-06-2027 deadline
neutral · No strike-offs in the KBO publications
We found no ex-officio strike-off or cessation. Our series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
KBO publications · our coverage

History

C.D. PHARMA was incorporated on 19 September 1997.1 Total assets fell from EUR 302,002 in 2018 to EUR 270,629 in 2025.2

  1. 1Crossroads Bank for Enterprises
  2. 2National Bank, annual accounts 2018 and 2025

Go further with this company

Is this your company? See how customers and banks see it.

Investigating this company? Keep it with today's facts in a case file.

Financials · fiscal year 2025, micro schema

Turnover
Not included in this filing
EBIT margin
Not included in this filing
Net result
-€10,408▼ 2.5%
2024 · -€10,158
Working capital
-€244,841▼ 1.7%
2024 · -€240,813
Trend over the years

Click a name to add, emphasise or remove a line.

Every figure with its change against the fiscal year before
favourable unfavourable
Line20212022202320242025
Operating result-€9,261▼ 63.4%-€9,807▼ 5.9%-€10,117▼ 3.2%-€10,124▼ 0.1%-€10,377▼ 2.5%
Net result-€8,810▼ 69.9%-€9,638▼ 9.4%-€10,119▼ 5.0%-€10,158▼ 0.4%-€10,408▼ 2.5%
Equity€65,629▼ 11.8%€55,991▼ 14.7%€45,872▼ 18.1%€35,714▼ 22.1%€25,306▼ 29.1%
Total assets€296,161▲ 1.2%€289,340▼ 2.3%€282,957▼ 2.2%€277,041▼ 2.1%€270,629▼ 2.3%
Debt€230,363▲ 5.9%€233,349▲ 1.3%€237,085▲ 1.6%€241,327▲ 1.8%€245,323▲ 1.7%
Working capital-€229,871▼ 6.4%-€233,298▼ 1.5%-€237,036▼ 1.6%-€240,813▼ 1.6%-€244,841▼ 1.7%
Result per fiscal year
Operating resultNet result
-€15,000-€10,000-€5,000€0Operating result 2021: -€9,261-€9,261Net result 2021: -€8,810-€8,810Operating result 2022: -€9,807-€9,807Net result 2022: -€9,638-€9,638Operating result 2023: -€10,117-€10,117Net result 2023: -€10,119-€10,119Operating result 2024: -€10,124-€10,124Net result 2024: -€10,158-€10,158Operating result 2025: -€10,377-€10,377Net result 2025: -€10,408-€10,40820212022202320242025-€15,000-€10,000-€5,000€0Operating result 2023: -€10,117-€10,100Net result 2023: -€10,119-€10,100Operating result 2024: -€10,124-€10,100Net result 2024: -€10,158-€10,200Operating result 2025: -€10,377-€10,400Net result 2025: -€10,408-€10,400202320242025
The operating result stays negative: a loss of €10,377 in 2025 against €10,124 in 2024; the loss grows and 2025 has the lowest result in the available series.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €270,629
Fixed assets €270,147 ▼ 2.3%
Current assets €482 ▼ 6.2%
Equity and liabilities €270,629
Equity €25,306 ▼ 29.1%
Debt €245,323 ▲ 1.7%
Debt's share of the balance-sheet total rises from 87.1% to 90.6%. Equity is lower and debt is higher.
Key figures and ratios
2025 value · change against 2024
EBITDA
-€3,996▼
2024 · -€3,743
Cash flow
-€4,027▼
2024 · -€3,777
Current ratio
0.00▼
2024 · 0.00
Debt to equity
9.69▲
2024 · 6.76
ROE
-41.1%▼
2024 · -28.4%
ROA
-3.8%▼
2024 · -3.7%
Interest coverage
-128.90▼
2024 · -110.09
Debt ≤ 1 year
€245,323▲
2024 · €241,327
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Annual accounts
Filed annual accounts As filed with the NBB · 2025 against 2024 · 29 lines
Balance sheet Code20242025
Assets
Total assets20/58€277,041€270,629▼
Fixed assets21/28€276,527€270,147▼
Tangible fixed assets22/27€91,510€85,130▼
Land and buildings22€91,510€85,130▼
Financial fixed assets28€185,017€185,017=
Current assets29/58€514€482▼
Current investments50/53€514€482▼
Equity and liabilities
Total equity and liabilities10/49€277,041€270,629▼
Equity10/15€35,714€25,306▼
Contributions10/11€6,205€6,205=
Reserves13€97,694€97,694=
Non-distributable reserves130/1€1,860€1,860=
Reserves not available under the articles1311€1,860€1,860=
Distributable reserves133€95,834€95,834=
Profit (loss) carried forward14-€68,185-€78,593▼
Amounts payable17/49€241,327€245,323▲
Amounts payable within one year42/48€241,327€245,323▲
Other amounts payable47/48€241,327€245,323▲
Income statement Code20242025
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€6,381€6,381=
Other operating charges640/8€2,385€2,457▲
Gross operating margin9900-€1,358-€1,539▼
Operating profit (loss)9901-€10,124-€10,377▼
Financial charges65/66B€34€31▼
Recurring financial charges65€34€31▼
Profit (loss) for the period before taxes9903-€10,158-€10,408▼
Profit (loss) for the period9904-€10,158-€10,408▼
Profit (loss) for the period to be appropriated9905-€10,158-€10,408▼
Appropriation of the result
Profit (loss) to be appropriated9906-€68,185-€78,593▼
Profit (loss) brought forward from the previous period14P-€58,027-€68,185▼

The notes to these accounts (5 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.

Line20212022202320242025Change
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€5,951€6,381€6,381€6,381€6,381=
Other operating charges640/8€2,027€2,111€2,308€2,385€2,457▲ 3.0%
Gross operating margin9900-€1,283-€1,315-€1,428-€1,358-€1,539▼ 13.3%
Operating profit (loss)9901-€9,261-€9,807-€10,117-€10,124-€10,377▼ 2.5%
Financial charges65/66B€71-€2€34€31▼ 8.8%
Recurring financial charges65€71-€2€34€31▼ 8.8%
Profit (loss) for the period before taxes9903-€9,332-€9,807-€10,119-€10,158-€10,408▼ 2.5%
Transfer from deferred taxes780€522€169----
Profit (loss) for the period9904-€8,810-€9,638-€10,119-€10,158-€10,408▼ 2.5%
Transfer from tax-exempt reserves789€1,015€328----
Profit (loss) for the period to be appropriated9905-€7,795-€9,310-€10,119-€10,158-€10,408▼ 2.5%
Line20212022202320242025Change
Assets
Total assets20/58€296,161€289,340€282,957€277,041€270,629▼ 2.3%
Fixed assets21/28€295,669€289,289€282,908€276,527€270,147▼ 2.3%
Tangible fixed assets22/27€110,652€104,272€97,891€91,510€85,130▼ 7.0%
Land and buildings22€110,652€104,272€97,891€91,510€85,130▼ 7.0%
Financial fixed assets28€185,017€185,017€185,017€185,017€185,017=
Current assets29/58€492€51€49€514€482▼ 6.2%
Current investments50/53€492€51€49€514€482▼ 6.2%
Equity and liabilities
Total equity and liabilities10/49€296,161€289,340€282,957€277,041€270,629▼ 2.3%
Equity10/15€65,629€55,991€45,872€35,714€25,306▼ 29.1%
Contributions10/11€6,205€6,205€6,205€6,205€6,205=
Reserves13€98,022€97,694€97,694€97,694€97,694=
Non-distributable reserves130/1€1,860€1,860€1,860€1,860€1,860=
Reserves not available under the articles1311€1,860€1,860€1,860€1,860€1,860=
Tax-exempt reserves132€328-----
Distributable reserves133€95,834€95,834€95,834€95,834€95,834=
Profit (loss) carried forward14-€38,598-€47,908-€58,027-€68,185-€78,593▼ 15.3%
Provisions and deferred taxes16€169-----
Deferred taxes168€169-----
Amounts payable17/49€230,363€233,349€237,085€241,327€245,323▲ 1.7%
Amounts payable within one year42/48€230,363€233,349€237,085€241,327€245,323▲ 1.7%
Trade debts44€404-----
Suppliers440/4€404-----
Other amounts payable47/48€229,959€233,349€237,085€241,327€245,323▲ 1.7%
Line20212022202320242025Change
Profit (loss) for the period9904-€8,810-€9,638-€10,119-€10,158-€10,408▼ 2.5%
+ Depreciation and write-downs630€5,951€6,381€6,381€6,381€6,381=
Operating cash flow (approximation)-€2,859-€3,257-€3,738-€3,777-€4,027▼ 6.6%
Investment in fixed assets (approximation)--€1€0€0-€1-

Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.

Download as CSV

Timeline · acts, filings and financial milestones

Next filing, fiscal year 2026, expected by 30-06-2027
2026
12-05
NBB filing Annual accounts filed
fiscal year 2025 · micro schema
2025
30-11
Financial Weakest financial yearnet -€10,408
Net result drops to -€10,408, the lowest in the series.
05-06
NBB filing Annual accounts filed
fiscal year 2024 · micro schema
2024
14-05
NBB filing Annual accounts filed
fiscal year 2023 · micro schema
2023
23-05
NBB filing Annual accounts filed
fiscal year 2022 · micro schema
2022
02-06
NBB filing Annual accounts filed
fiscal year 2021 · full schema
2021
07-05
NBB filing Annual accounts filed
fiscal year 2020 · full schema
2020
22-05
NBB filing Annual accounts filed
fiscal year 2019 · full schema
2019
24-06
NBB filing Annual accounts filed
fiscal year 2018 · full schema
2018
27-06
NBB filing Annual accounts filed
fiscal year 2017 · full schema
2017
24-05
NBB filing Annual accounts filed
fiscal year 2016 · full schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
0 of 1 act read
About the unread acts

We know of 1 Belgian State Gazette act for this company. It has not been read yet: what they contain is neither established nor disproved here.

Have them read with priority Sign in to place this company at the front of the reading queue.

Directors · office · real estate

Directors
1 act for this company is in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Nivelles · 1 establishment unit since 1998
seat establishment The establishment unit on the map
Ground area
693 m²
Building footprint
106 m²
Volume, LiDAR
702 m³
Parcel 25782C0382/00B004, Wallonia · tallest building 8.4 m, ±2 floors. Linked by address, not a title deed.
4 companies at this address See who is registered here
1 establishment unit
Allée de la Tour-Renard 15, 1400 Nivelles
NACE 74151
since 19982.085.477.135
1 parcel
Wallonia 1 (100%)
Parcel (capakey) Region Area Buildings Height / fl.
25782C0382/00B004 Wallonia 693 m² 1 · 106 m² 8.4 m · 2 fl.
Linked by address, not proof of ownership
Good to know
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.

Structure & network

Owners and holdings

1 holding

Owners 0

The accounts to 30-11-2025 list no shareholders, and no other source names one.

Holdings 1

According to the annual accounts to 30-11-2025 of C.D. PHARMA and those of the other companies, the acts in the Belgian Gazette and the LEI register. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not fill in these statements, or need not, is missing.

Connections & network

No current directors or connected companies found in the register.

Identification & contact

Identification
Legal formPrivate limited company (pre-2019)
Founded19-09-1997
Fiscal year end30-11
E-invoicing
Not found in the Peppol register

No Peppol card under this enterprise or VAT number. That proves nothing: publishing a card is voluntary.

What can you do?

Try sending from your invoicing software; if that fails, ask the customer whether they already receive via Peppol.

If the customer is not ready yet, you may send the invoice another way, for example as a PDF; if electronically, with their agreement on a secure alternative. That invoice is valid; the customer risks a penalty. FPS Finance

Register as of 28 September 2026 · Peppol Directory

Scores and ratios are computed by Checked and are not a credit decision.